Pulmonary and Critical Care content for learners and practitioners of all levels
The DEXA-ARDS trial, published in Lancet Respiratory Medicine in 2020, evaluates the efficacy of dexamethasone in treating moderate to severe acute respiratory distress syndrome. Administering 20 milligrams of dexamethasone daily for five days followed by 10 milligrams for another five days significantly reduces 60-day...
Prone positioning significantly improves survival in patients with severe acute respiratory distress syndrome (ARDS), as demonstrated by the 2013 PROSEVA trial. By transitioning patients with a P/F ratio under 150 to a prone position for at least 16 hours daily, clinicians achieve a 16.8% absolute reduction in 28-day m...
The ROSE trial, published in 2019, fundamentally shifted clinical understanding of neuromuscular blockade in patients with early, severe acute respiratory distress syndrome (ARDS). By comparing 48 hours of deep sedation and paralysis against a light sedation strategy, the study demonstrated no mortality benefit, leadin...
The FACTT trial evaluates the impact of conservative versus liberal fluid management strategies on outcomes for patients with Acute Respiratory Distress Syndrome (ARDS). By comparing these approaches, the study reveals that while a conservative strategy—targeting lower central venous or pulmonary artery wedge pressures...
Lung-protective ventilation, defined by tidal volumes of 6 cc/kg of predicted body weight and plateau pressures below 30 cm H2O, remains the cornerstone of ARDS management due to the landmark ARMA trial. Published in 2000, this study challenged the traditional practice of using large tidal volumes (10–15 cc/kg) to norm...
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
